Navigation Links
Vascular Medcure Receives Third FDA Clearance for CAPERE® Thrombectomy System – a Mechanical Device for Treatment of DVT
Date:12/6/2019

Southern California medical device manufacturer Vascular Medcure, Inc. has received FDA 510(k) clearance for its latest CAPERE® Thrombectomy System for peripheral vascular, deep vein thrombosis (DVT) treatment. The company’s early clinical data suggests the CAPERE® offers great benefits for first-in-line treatment for nonsurgical removal of soft emboli and thrombi without the need for aspiration, thrombolytics, or capital equipment.

“We are very pleased to receive FDA 510(k) clearance for our latest CAPERE® thrombectomy catheter that significantly expands the treatment options for physicians. We have also received our ninth U.S. patent on the technology and are excited about the potential of CAPERE® to improve patient outcomes and reduce costs for the healthcare system,” Vascular Medcure CEO, Samuel Shaolian said.

Mr. Shaolian further stated, “The CAPERE® Thrombectomy System does not use thrombolytics which may be a significant time saver in busy care facilities. With no capital equipment required, the CAPERE® Thrombectomy System is a cost effective, low-profile, 8Fr, over-the-wire approach, that provides interventional radiologists and interventional cardiologists on the table results, when treating these challenging patients.”

The CAPERE® Thrombectomy System, which utilizes its patented, dynamic basket technology, was developed to provide a mechanical thrombectomy approach for fast and effective treatment of patients with deep vein thrombosis and to provide on the table results. CAPERE® is designed to offers significant improvement over existing products by not requiring the use of aspiration – whereby minimizing blood loss, thrombolytics, or expensive capital equipment.

For more information, visit http://www.vascularmedcure.com

Contact:

David Mills, Vice President of Sales & Marketing
David@vascularmedcure.com

Read the full story at https://www.prweb.com/releases/vascular_medcure_receives_third_fda_clearance_for_capere_thrombectomy_system_a_mechanical_device_for_treatment_of_dvt/prweb16766589.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. uBiome Awards Grant to North Carolina A&T State University to Study Gut Microbiome and Cardiovascular Health Risks in African-American Athletes
2. New Stago Webinar Offers Insight on Coagulation Testing for Disseminated Intravascular Coagulation
3. Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners
4. Dr. Steven Brooks, Former FDA Medical Officer, Peripheral Vascular Device Branch, Office of Device Evaluation, Joins NDA Partners
5. Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease
6. Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
7. Cardiovascular Medical Devices: World Market, Industry, Trends and Revenue Forecasts 2015-2025
8. CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine
9. Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD
10. QT Vascular Announces The Allowance Of Four New Patents
11. Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... Mass. (PRWEB) , ... January 08, 2020 , ... ... clad metal wire composites that can achieve specific properties for use in harsh ... Clad Metal Wire combines up to three metals or alloys to achieve ...
(Date:1/7/2020)... ... 07, 2020 , ... Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated ... appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to ... are delighted to welcome Chand and Lee as new directors. They will be of ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... cohort of emerging biosciences ventures invited to participate in the annual program. Twelve ... fundable business plans and a professional network. All startups will receive an entrepreneur ...
(Date:12/30/2019)... (PRWEB) , ... December 30, 2019 , ... ... built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food ... 1.11.19 21 CFR Part 11 compliant software program specific to the custom-built helium ...
Breaking Biology Technology:
(Date:1/24/2020)... Conn. (PRWEB) , ... January 24, 2020 , ... ... down to the strain level, today announced that the company will debut a novel ... January 26-29. , The new product, Shoreline Biome's Rapid Prep kit, is a ...
(Date:1/23/2020)... ... , ... GIOSTAR/HEAMGEN has developed and secured patented ... red blood cells are made utilizing a bioreactor that permits the production of ... the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood ...
(Date:1/22/2020)... , ... January 21, 2020 ... ... in integrating cold chain operations, developing transport validation strategies, supporting global regulatory ... both Inc. 5000 and the Houston Business Journal as a fastest growing ...
Breaking Biology News(10 mins):